L-870812 | CAS#410545-90-3 | bioactive chemical

MedKoo Cat#: 559075 | Name: L-870812

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-870812 is a bioactive chemical.

Chemical Structure

L-870812

CAS#410545-90-3

Theoretical Analysis

MedKoo Cat#: 559075

Name: L-870812

CAS#: 410545-90-3

Chemical Formula: C21H20FN5O4

Exact Mass: 425.1499

Molecular Weight: 425.42

Elemental Analysis: C, 59.29; H, 4.74; F, 4.47; N, 16.46; O, 15.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L-870812; L 870812; L870812; L-870,812; L 870,812; L870,812;

IUPAC/Chemical Name

N1-(7-((4-fluorobenzyl)carbamoyl)-8-hydroxy-1,6-naphthyridin-5-yl)-N1,N2,N2-trimethyloxalamide

InChi Key

DKMXWAOCNKDQMT-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H20FN5O4/c1-26(2)20(30)21(31)27(3)18-14-5-4-10-23-15(14)17(28)16(25-18)19(29)24-11-12-6-8-13(22)9-7-12/h4-10,28H,11H2,1-3H3,(H,24,29)

SMILES Code

CN(C(C(N(c1nc(C(NCc2ccc(F)cc2)=O)c(O)c3c1cccn3)C)=O)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 425.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F, Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E, Villinger F. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat Methods. 2015 May;12(5):427-32. doi: 10.1038/nmeth.3320. Epub 2015 Mar 9. PubMed PMID: 25751144; PubMed Central PMCID: PMC4425449. 2: Ling B, Piatak M Jr, Rogers L, Johnson AM, Russell-Lodrigue K, Hazuda DJ, Lifson JD, Veazey RS. Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques. PLoS One. 2014 Jul 17;9(7):e102795. doi: 10.1371/journal.pone.0102795. eCollection 2014. PubMed PMID: 25033210; PubMed Central PMCID: PMC4102539. 3: Dobard C, Sharma S, Parikh UM, West R, Taylor A, Martin A, Pau CP, Hanson DL, Lipscomb J, Smith J, Novembre F, Hazuda D, Garcia-Lerma JG, Heneine W. Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci Transl Med. 2014 Mar 12;6(227):227ra35. doi: 10.1126/scitranslmed.3007701. PubMed PMID: 24622515. 4: Ling B, Rogers L, Johnson AM, Piatak M, Lifson J, Veazey RS. Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 2013 Nov;29(11):1465-74. doi: 10.1089/AID.2012.0378. Epub 2013 Mar 8. PubMed PMID: 23387294; PubMed Central PMCID: PMC3809389. 5: Terrazas-Aranda K, Van Herrewege Y, Hazuda D, Lewi P, Costi R, Di Santo R, Cara A, Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother. 2008 Jul;52(7):2544-54. doi: 10.1128/AAC.01627-07. Epub 2008 May 12. PubMed PMID: 18474579; PubMed Central PMCID: PMC2443891. 6: Pandey KK, Bera S, Zahm J, Vora A, Stillmock K, Hazuda D, Grandgenett DP. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol. 2007 Nov;81(22):12189-99. Epub 2007 Sep 5. PubMed PMID: 17804497; PubMed Central PMCID: PMC2169005. 7: Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004 Jul 23;305(5683):528-32. Epub 2004 Jul 8. PubMed PMID: 15247437.